EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NFL Biosciences's Enterprise Value is €20.80 Mil.
NFL Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, NFL Biosciences's EV-to-FCF for today is .
The historical rank and industry rank for NFL Biosciences's EV-to-FCF or its related term are showing as below:
XPAR:ALNFL's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.31 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for NFL Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NFL Biosciences's EV-to-FCF
For the Biotechnology subindustry, NFL Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NFL Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NFL Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NFL Biosciences's EV-to-FCF falls into.
NFL Biosciences's current Enterprise Value is €20.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NFL Biosciences's PE Ratio for today is calculated as:
NFL Biosciences's share price for today is €2.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.479.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NFL Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of NFL Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALNFL has been successfully added to your